You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
H
Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Plasma Cell Leukemia
  • CAR-T (CAR-GPRC5D)
  • (no location specified)
2022-01-20
Jan 20, 2022
E
Active, not recruiting
  • Plasma Cell Neoplasm
  • Pneumococcal 13-valent Conjugate Vaccine
  • Trivalent Influenza Vaccine
  • Atlanta, Georgia
  • +1 more
2022-01-24
Jan 24, 2022
U
Recruiting
  • Plasma Cell Leukemia
  • +2 more
  • Biospecimen Collection
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-10-18
Oct 18, 2021
U
Recruiting
  • Multiple Myeloma
  • +8 more
    • Chapel Hill, North Carolina
      North Carolina Cancer Hospital
    2021-11-30
    Nov 30, 2021
    M
    Recruiting
    • Plasma Cell Dyscrasia
    • Home monitoring teleconsult visits
    • +2 more
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    2022-03-24
    Mar 24, 2022
    P
    Recruiting
    • Multiple Myeloma
    • +11 more
    • No intervention
    • Beijing, China
      Peking University First Hospital
    2022-03-16
    Mar 16, 2022
    M
    Completed
    • Recurrent Plasma Cell Myeloma
    • Refractory Plasma Cell Myeloma
    • Laboratory Biomarker Analysis
    • +2 more
    • Rochester, Minnesota
      Mayo Clinic
    2021-12-01
    Dec 1, 2021
    C
    Active, not recruiting
    • Recurrent Plasma Cell Myeloma
    • Refractory Plasma Cell Myeloma
    • Laboratory Biomarker Analysis
    • +2 more
    • Duarte, California
      City of Hope Medical Center
    2021-10-04
    Oct 4, 2021
    R
    M
    Recruiting
    • Recurrent Plasma Cell Myeloma
    • Daratumumab
    • Houston, Texas
      M D Anderson Cancer Center
    2021-12-22
    Dec 22, 2021
    E
    Active, not recruiting
    • ISS Stage I Plasma Cell Myeloma
    • +4 more
    • Pembrolizumab
    • Radiation Therapy
    • Atlanta, Georgia
      Emory University/Winship Cancer Institute
    2022-03-02
    Mar 2, 2022
    C
    Active, not recruiting
    • Smoldering Plasma Cell Myeloma
    • Duarte, California
      City of Hope Medical Center
    2021-08-11
    Aug 11, 2021
    M
    Active, not recruiting
    • Plasma Cell Myeloma
    • Basking Ridge, New Jersey
    • +5 more
    2021-09-01
    Sep 1, 2021
    U
    Not yet recruiting
    • Multiple Myeloma
    • (no location specified)
    2021-12-15
    Dec 15, 2021
    S
    Recruiting
    • Multiple Myeloma
    • Saint Petersburg, Russian Federation
      Boris V Afanasyev, MD, Prof.
    2022-04-04
    Apr 4, 2022
    E
    Not yet recruiting
    • Plasma Cell Myeloma
    • Pembrolizumab
    • Atlanta, Georgia
      Emory University
    2022-02-21
    Feb 21, 2022
    B
    No longer available
    • Multiple Myeloma
    • Elotuzumab
    • (no location specified)
    2021-11-17
    Nov 17, 2021
    M
    Recruiting
    • Myeloma
    • MGUS
    • Infusion of 13-Carbon labeled Glutamine
    • Rochester, Minnesota
      Mayo Clinic
    2022-02-10
    Feb 10, 2022
    I
    Recruiting
    • Plasma Cell Dyscrasias
    • This is a non-interventional trial
    • Indianapolis, Indiana
      Indiana University Simon Cancer Center
    2022-03-02
    Mar 2, 2022
    J
    Recruiting
    • Multiple Myeloma
    • Shanghai, Shanghai, China
      Shanghai Changzheng Hospital
    2022-03-03
    Mar 3, 2022
    M
    Recruiting
    • Myeloma Multiple
    • Lymphoma
    • Vitamin C
    • Placebos
    • Maastricht, Limburg, Netherlands
      MUMC+
    2021-09-23
    Sep 23, 2021
    M
    Recruiting
    • Smoldering Plasma Cell Myeloma
    • Isatuximab
    • Laboratory Biomarker Analysis
    • New York, New York
    • +2 more
    2021-11-30
    Nov 30, 2021
    H
    Recruiting
    • Multiple Myeloma
    • Autologous Stem Cell Transplant
    • +2 more
    • Tampa, Florida
      Moffitt Cancer Center
    2022-02-28
    Feb 28, 2022
    H
    Recruiting
    • Multiple Myeloma
    • Plasma Cell Disorder
    • Atlanta, Georgia
    • +5 more
    2022-03-10
    Mar 10, 2022